Mosaic ImmunoEngineering, Inc. (OTCMKTS:CPMV) Short Interest Update

Mosaic ImmunoEngineering, Inc. (OTCMKTS:CPMV) was the recipient of a large decline in short interest in December. As of December 31st, there was short interest totalling 200 shares, a decline of 66.7% from the December 15th total of 600 shares. Based on an average daily trading volume, of 800 shares, the short-interest ratio is currently 0.3 days.

Mosaic ImmunoEngineering Stock Performance

Shares of OTCMKTS CPMV traded down $0.03 during midday trading on Monday, reaching $0.94. The stock had a trading volume of 297 shares, compared to its average volume of 1,600. The company has a market capitalization of $6.81 million, a price-to-earnings ratio of -6.27 and a beta of 0.27. The stock has a 50-day moving average of $0.89 and a 200-day moving average of $0.85. Mosaic ImmunoEngineering has a 12-month low of $0.10 and a 12-month high of $1.13.

Mosaic ImmunoEngineering Company Profile

Mosaic ImmunoEngineering, Inc, a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals.